CELLETS® technology enables innovative biologics gastrointestinal tract OSD therapy

Pharmatrans SANAQ has introduced a groundbreaking solid oral formulation technology that enables sustained release of antibodies in the lower gastrointestinal tract from an oral solid dose (OSD) medicine.

It has applied for patent US20250127722A1 (2025) that describes novel methods and formulations that enhance antibody stability and bioavailability within the gastrointestinal environment, marking a significant leap forward in biologic oral administration. This cutting-edge solution addresses the traditional challenges of oral biologic delivery, ensuring controlled and prolonged release for maximum therapeutic efficacy.

Innovative microencapsulation approach

This innovative approach leverages advanced microencapsulation technology and the unique properties of CELLETS®, microcrystalline cellulose (MCC) pellets that serve as inert cores for controlled-release drug systems. These properties include highly uniform sphericity, particle size, stability and mechanical strength. Together, they provide a stable, uniform platform for layering active pharmaceutical ingredients (APIs), enabling precise and targeted delivery deep into the gut.

CELLETS® are integral to this innovative formulation due to their unique physical and chemical attributes. As inert, insoluble carriers made entirely of microcrystalline cellulose, they do not interact with the APIs, maintaining drug stability and efficacy. Their high sphericity, narrow particle size distribution, and excellent mechanical strength contribute to consistent coating and controlled release profiles.

Additionally, CELLETS® exhibit high abrasion resistance, facilitating uniform API coating and minimizing fines during processing, both ensuring reliable dosing and performance. Their stability and robustness make them an ideal choice for developing sophisticated controlled-release formulations, offering reproducibility and high therapeutic value.

Precision match to application

The CELLETS-based technology covered by patent US20250127722A1 unlocks new therapeutic possibilities for chronic and inflammatory intestinal diseases, improving patient compliance and enabling more effective, less invasive treatment options via a versatile platform that ensures the consistent, reliable, and sustained release of active compounds. The patented approach shows how the Pharmatrans SANAQ^® combination of patented innovations and pharmaceutical expertise can foster next-generation healthcare solutions.

Pharmatrans Sanaq is the leading distributor of CELLETS® as a pharma excipient in selected markets and offers  them, in a very wide range of particle sizes and PSD profiles, from CELLETS® 100 to CELLETS® 1000, to meet the whole spectrum of sophisticated controlled-release formulations, offering reproducibility and high therapeutic value.

In this case, being able to specify exactly the right size of core to match the API was also a factor in the solution’s effectiveness, with CELLETS® 127 (particle size ranging from 100 μm to 160 μm) employed to optimize surface area for API layering and ensure desirable flow and compressibility properties. This precise sizing fosters a balance between mechanical strength and drug release kinetics, ultimately leading to enhanced patient outcomes.

Overcoming personalized medicine challengers

As pharmaceutical drug developers face increasingly complex demands for flexible, patient-centric, and personalized medicine  dosage forms with more sophisticated drug release profiles, it becomes more important than ever to choose precision-engineered excipients. These can be very powerful in overcoming problems caused by ‘difficult’ APIs to streamline production and ensure consistent performance, enabling more advanced OSD solutions.

The use of CELLETS® 127 as inert cores in the innovative approach described in patent US20250127722A1 underlines the influential role that CELLETS can play in optimizing formulations for controlled sustained drug release. By combining highly engineered excipients with advanced biologic APIs, it opens new horizons in oral biologic therapies, promising safer, more effective, and patient-friendly treatment options.

Resources

Click on US20250127722A1 Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract to learn more about the patent.
Click on Pharmatrans SANAQ CELLETS® for further information.